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Abstract
Recent studies describe new genome-wide mutagenesis strategies, coupled with phenotypic
screening, and demonstrate the power of such approaches to provide new insights into the
genetics of the immune response.
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A spate of recent articles in Nature, Journal of Biology, and
Immunity [1-4] herald the ripened fruit of mutagenic and
genomic approaches to dissecting the molecular mecha-
nisms of immunity. Genetics has long been of central impor-
tance in elucidating the nature of immune responses, its
roots extending at least as deeply as the establishment of
systems for understanding histocompatibility and immune
regulation. The ‘pre-genomic’ era produced insights into
autoimmune-disease susceptibility using the non-obese
diabetic  (NOD) strain of mice [5]. Somatic-cell mutants
unresponsive to interferons were generated and character-
ized, thereby leading understanding of Jak-STAT signaling
pathways [6-8]. The TLR4 gene was identified as the basis
for lipopolysaccharide (LPS) unresponsiveness in C3H/HeJ
mice [9], and a mutated NF-B-inducing kinase gene was
found to be the cause of the alymphoid (aly) mutant mouse
strain [10]. Moving into the post-genomic era, these exciting
precedents have inspired systematic attacks on the genera-
tion and analysis of mutant mouse strains to achieve a
greater saturation of the gene pool and screening of these
strains for immune system phenotypes. Papers exemplifying
each of several mutational approaches establish that global
mutagenic strategies are already paying dividends in new
understanding and promise even greater yields in the future.
At least four systematic approaches are now in use, employ-
ing oncoretroviruses or chemical mutagenesis, in cell lines or
mice. Because of the greater ease and lower costs of screen-
ing and selection strategies with mammalian cell lines rather
than whole animals, cellular approaches have provided some
of the earliest targets and success stories of genome-wide
approaches [6,7,11,12]. Evidence that Carma1/CARD11, a
member of the MAGUK (signaling-associated scaffold) family
of proteins, is essential for induction of NF-B transcription
factors by the T-cell receptor (TCR) and CD28, is one recent
finding that exemplifies the success of such strategies for
studying immune regulation [13]. In this study, a powerful
screening strategy was implemented in a widely used human
T-cell line, Jurkat. A synthetic NF-B-dependent promoter
was used to govern the expression of green fluorescent
protein (GFP) and chemically mutagenized cells were identi-
fied that were deficient in the induction of GFP in response to
activation of the TCR but normal in terms of the response to
stimulation by tumor necrosis factor  (TNF). From a panel
of such cells with a selective block to signaling, one variant
was shown to be deficient in Carma1, a defect reversed by
restoration of Carma1 expression. This mutation caused a
loss of NF-B induction as a result of defective relays between
the cell surface and the transcription factor, and also dimin-
ished TCR-induced activation of the JNK but not the ERK
subtype of mitogen activated protein (MAP) kinase [13]. 
Retroviral mutagenesis methods 
Although an antecedent to results from concerted mouse-
based mutagenesis work, the ability to use cell lines in
genome-wide approaches is impacted by issues of ploidy,
genetic variation, and barriers to mapping studies using
somatic cells. Instead of an approach such as that described
above, which is oriented to recessive mutations, more recentwork has used a screening strategy based on dominant
mutations in Jurkat cells [2]. For this study, a novel retrovec-
tor was generated that permits tetracycline regulation of the
expression of inserted cDNAs (Figure 1). The vector is repli-
cation-deficient because the promoters of the retroviral long
terminal repeats have been mutated, and it carries a GFP
cDNA to allow selection of transduced cells. After insertion of
mutated cDNA libraries into this retrovector downstream of a
tetracycline-inducible promoter and transduction of the
Jurkat T-cell line, individual cells were screened by fluores-
cence-activated cell sorting to identify those exhibiting
decreased expression of a marker, CD69, known to be down-
stream from TCR ligation. Importantly, this study validated
the ability to identify scores of genes for which mutations
(generated while creating the cDNA library) attenuated TCR
signaling to the CD69 gene [2]. Furthermore, the incorpora-
tion of an on-off system controlling expression of the cDNA
made a critical screening step possible by simple reversion
testing - loss of the mutant phenotype when the expression of
the cDNA insert was turned off. The completion of genome
sequences and availability of tools sufficiently robust to
handle the numbers of cDNAs screened (2,828 in the study in
question [2], of which 1,323 were validated by reversion) link
this approach to the post-genomic era.
Such a cell-based, dominant selection system offers a power-
ful tool for the identification of molecules that impact a sig-
naling pathway, albeit at the cost of several drawbacks.
Discovery will be limited to those molecules for which domi-
nant negatives have an effect on the pathway, and there will
be inherent pitfalls in the use of any cell line: for example,
lipid-kinase signaling in most Jurkat T cells will be abnormal
because of pre-existing loss-of-function mutations in the
PTEN lipid phosphatase/tumor suppressor genes. Nonethe-
less, this or analogous retrovector systems can be used for
the transduction of primary lymphocytes to perform further
validation. Intriguingly, variations on this approach offer
potentially great power in structure-function analyses with
selected molecules. Single cDNAs could be subjected to high-
density mutagenesis and, through the on-off capabilities of
the approach, microarray analyses would allow measure-
ment of the changes in global gene-expression profiles that
result from graded interference with a given pathway. 
The applicability of a finding to immune regulation ultimately
depends on its validation in the immune response of animals.
In principle, such retroviral technologies could also be
applied to the transduction of hematopoietic cells (for
example, lymphocytes or dendritic cells) derived from mouse
lines in which loss-of-function mutations have been engi-
neered by other approaches. This extension of the approach
could allow high-throughput structure-function screening in
primary cells independent of the need to achieve dominant-
negative effects. In parallel, however, enhanced techniques
for random mutagenesis, phenotypic screening, and gene
identification have been important goals. To facilitate the
process of cloning mutated genes after mutagenesis, another
class of mutagen takes advantage of the fact that retrovirus
insertion in the genome can be engineered so as to achieve
loss-of-function mutations at high efficiencies ([14]; reviewed
in [15]). In particular, vectors based on oncoretroviruses are
modified to encode a selectable trait whose expression
depends on insertion into an active transcription unit. After
bulk infection of pluripotent embryonic stem (ES) cells with
high-titre retrovirions, individual clones can be micro-
injected and transmitted to the germ line, so that progeny can
be mated to homozygosity. As an example of the early success
and potential of this strategy of retroviral mutagenesis, a
novel link was identified between the mouse FUS gene, chro-
mosomal stability, and B-lymphoid proliferation [16]. This
technology promises to provide further successes, which will
be facilitated by the creation of banks of mutated ES cells for
which a sequence tag identifying the mutated gene is publicly
accessible. Two examples of ES-cell banks currently available
are from a for-profit company, Lexicon Genetics [17], and a
program funded by the National Heart Lung and Blood Insti-
tute and linked to BayGenomics [18].
Ethylnitrosourea mutagenesis screens
Progress in genome sequencing and annotation, and satura-
tion with sufficient genetic markers for gene mapping, have
dramatically enhanced our capacity to identify a gene
mutated by chemical mutagens that create point mutations.
These capabilities, coupled to recognition of the powerful
advantages of ethylnitrosourea (ENU) as a mutagen [19], set
the stage for several of the recent successes noted at the
beginning of this article. ENU is a highly efficient mutagen,
able to create multiple mutations in the germ line of each
male breeder, which can be coupled with breeding strategies
to perform recessive screens (Figure 2) [20-22]. In the case
of mice with mutations in the Lps2 gene, this approach has
revealed an essential component of signaling by some, but
not all, Toll-like receptors (TLRs) operating as part of a
pathway independent of the MyD88 relay protein [1,23].
Mutagenesis and screening for defects in ex vivo production
of TNF by macrophages were initiated on an extensively
used inbred genetic background, C57BL/6. Notably, this
work involved approximately 2,650 G1 mice, heterozygous
for any mutation, and around 4,600 G3 mice, bred for the
generation of homozygotes, underscoring some of the cost
and logistical issues in such screens. The authors of these
studies [1,23] focused on a homozygote whose macrophage
response to endotoxin (lipopolysaccharide) and double-
stranded RNA was abrogated while activators of other TLRs
elicited normal TNF responses. Gene mapping and high-
throughput sequencing identified a mutation in the gene
encoding a previously known adapter protein, Trif/Ticam-1,
that leads to a small carboxy-terminal substitution. Although
this gene product had already been implicated in TLR signal-
ing, the Lps2 mutant mouse lines establish several novel fea-
tures of the both the protein (Trif/Ticam-1) and the
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Genome Biology 2003, 4:239MyD88-independent signaling pathway. In particular, these
studies make clear the essential role of the Trif/Ticam-1
protein in signaling by several members of the TLR gene
family, including some whose signaling also uses MyD88.
The results also indicate that other TLRs use an Lps2-inde-
pendent, MyD88-dependent means of signaling. 
Another triumph of functional screening at a genome-wide
level has emerged from a separate program, resulting from
similar ENU mutagenesis and recessive screening in the
same C57BL/6 background [3,4]. This large-scale program
focussed on the identification of mutations leading to
immune dysregulation [22]. Founder mice were identified
by a quantitative screen that detected differences in the
profile of surface immunoglobulin M (sIgM) on circulating B
lymphocytes that also carried IgD. In addition to a two-fold
increase in sIgM, closer examination also revealed a modest
increase in another molecule linked to signaling, CD21.
Gene mapping localized the point mutation to the
Carma1/CARD11 gene. Rather than a loss of expression, as
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Figure 1
A dominant strategy for the identification of signaling molecules using a tetracycline-regulated retrovector. A replication-defective retrovector was
generated in which the normal transcriptional promoters of the long terminal repeats were crippled (‘dead’ LTR), and a promoter (Tet-Reg) repressible
by the tetracycline trans-activator protein (tTA) in the presence of a tetracycline antibiotic, such as doxycycline, was inserted upstream from cloning
sites, an internal ribosomal entry sequence (IRES), and GFP cDNA. After cloning a library of mutated cDNAs into the vector, the DNA was packaged
into virions, and a large population of modified Jurkat T cells (carrying the tTA) was transduced with the virions; GFP expression was used to select
clones expressing a unique cDNA. Cells stimulated through their antigen receptor (TCR) were scored for retention of receptor expression and loss of
induction of a molecule downstream from TCR signaling, CD69. Individual clones could be re-scored for reversibility of the phenotype by comparison of
results in the presence (+tet) or absence (-tet) of doxycycline. Individual, sorted clones could then be used for isolation of the cDNA cloned into the
retrovector. Adapted from [2].
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tTAfound in the prior work in Jurkat cells (see above, [13]) and
concomitant papers using gene targeting [24,25], this ENU-
induced point mutation led to normal levels of a full-length
protein with altered function. Comparison of the conse-
quences of this mutation to the outcome of gene-targeting
experiments which eliminated Carma1 expression [24] is
illuminating in terms of what each strategy can offer. The
ENU mutant, which affects a coiled-coil region of the
protein, led to a phenotype far more prominent in B lympho-
cytes than their T-cell counterparts, while the lack of Carma1
in the loss-of-expression studies led to a profound impair-
ment of TCR/CD28-induced production of interleukin-2
(IL-2) and proliferation, along with B-cell signaling defects
[13,22,23]. Conversely, the point-mutant Carma1 led to a
partially penetrant hyper-IgE syndrome with other atopic
manifestations in the mice, whereas this abnormality was
not noted in the conventional knockouts. Thus, the random
generation of a point mutant uncovered new features of the
protein’s function in vivo and some selectivity in the impact
of these functional traits on particular lymphoid-cell types. 
So, what are the global lessons from these advances, and what
future refinements incorporating genome-wide approaches
may be possible? The first lesson is that these approaches
establish the ability of large, well-funded, and well-organized
operations to generate new insights into immune regulation
using functional-genomic screens. In addition, some of the
findings will differ from those obtained using conventional
knockouts. Subsequent to these initial ‘test-of-principle’
papers, the pace of discovery using this type of approach will
accelerate. The second lesson is that although there undoubt-
edly is some selection bias, a strikingly high frequency of ‘old
friends’ turn up in these screens. Thus far, most of the listed
gene products have been previously identified and implicated
in the relevant signaling pathways by conventional
approaches. This suggests that intensive gene discovery by
pre-genomic techniques has been quite successful. Nonethe-
less, because a substantial fraction of predicted genes do not
fall into known functional groups it is to be expected that the
gene products uncovered will extend more into groups not
previously linked to the functions being screened. Finally, the
collected findings indicate that it is already timely to be gener-
ating systems-based strategies to exploit these advances.
Approaches of this type will gain power as they are combined
and linked to other forms of genomics [26-28], proteomics
and systems analysis. Thus, for example, the tetracycline-reg-
ulated dominant retrovector system can be combined with
transductions of hematopoietic cells from mutant mice and to
microarrray analyses of gene-expression profiles. Such
approaches may allow the identification of selective roles of
protein modules and quantitation of the effects on function of
a wide range of sequence variants generated in vitro. Simi-
larly, when coupled to screens of protein-protein interactions
in cell lines, genome-scale approaches will rapidly increase
our insights into structure-function relationships in immunity
and disease.
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